Physician Education: Bridging Clinical Research and Patient Care

CME Webcast

CME Webcast

Please read this page before participating in this activity. At the bottom of the page, click on “I have read these instructions and understand them,” to begin activity.

Please note: Adobe Flash is needed to view webcasts. To download the latest version of Adobe Flash Player, please go to http://get.adobe.com/flashplayer/.

Maximizing the Benefits of Pree xposure Prophylaxis (PrEP)

Author(s): Susan P. Buchbinder, MD
Airdate: February 27, 2017 (41 minutes and 24 seconds)
Presented at: Improving the Management of HIV Disease®: An Advanced CME Live Course in HIV Pathogenesis, Antiretrovirals, and Other Selected Issues in HIV Disease Management
Co-Chair(s): Gerald H Friedland MD, Paul A Volberding MD

Grant support:

This course is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from commercial companies. Per IAS–USA policy, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Food and beverages at IAS–USA events are purchased with registration fees, not with grant support money. Generous support for this activity has been received from the following contributors.

PLATINUM SUPPORTER
ViiV Healthcare

GOLD SUPPORTER
Gilead Sciences, Inc

SILVER SUPPORTERS
Bristol-Myers Squibb
Janssen Therapeutics

BRONZE SUPPORTER
Merck

CME Information:

The International Antiviral Society–USA (IAS–USA) offers no CME credits for this webcast activity.

Disclosure of Financial Affiliations

In the interest of maintaining the independence of its continuing medical education (CME) activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (ie, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.

IAS–USA Board of Directors

Constance A. Benson, MD
Dr Benson serves on a data and safety monitoring board for GlaxoSmithKline/ViiV Healthcare. She has received research grants awarded to her institution from AbbVie, Gilead Sciences, Inc, and ViiV Healthcare. (Updated 05/22//17)

Peter Cassat, JD
Mr Cassat has no relevant financial affiliations to disclose. (Updated 05/30/12)

Judith S. Currier, MD
Dr Currier has no relevant financial affiliations to disclose. (Updated 05/02/17)

Carlos del Rio, MD
Dr del Rio has served as a consultant for InnaVirVax. (Updated 01/17/17)

Roy M. Gulick, MD, MPH
Dr Gulick has no relevant financial affiliations to disclose. (Updated 04/28/17)

Donna M. Jacobsen
Ms Jacobsen has no relevant financial affiliations to disclose. (Updated 05/24/17)

Jeanne M. Marrazzo, MD, MPH
Dr Marrazzo has no relevant financial affiliations to disclose. (Updated 01/13/17)

Douglas D. Richman, MD
Dr Richman has been a consultant to Antiva Biosciences, Chimerix, Gilead Sciences, Inc,, Merck, and Monogram Biosciences, Inc. (Updated 5/24/17)

Michael S. Saag, MD
Dr Saag has received research grants and support awarded to his institution from AbbVie, Bristol-Myers Squibb, Gilead Sciences, Inc, Merck, and ViiV Healthcare. He has also served as a consultant for Bristol-Myers Squibb, Gilead Sciences, Inc, Merck, Teva Pharmaceutical Industries, Ltd, and ViiV Healthcare. (Updated 05/15/17)

Robert T. Schooley, MD
Dr Schooley serves as a consultant to CytoDyn and Antiva Biosciences. He is a stockholder of Antiva Biosciences and has stock options from CytoDyn. He serves as a Scientific Advisory Board Member (honoraria remitted to the University of California) for Gilead Sciences, Inc, and LabCorps. (Updated 05/04/17)

Paul A. Volberding, MD
Dr Volberding has served on data and safety monitoring boards for Merck. (Updated 02/24/17)

Course Faculty and Staff:

Dr Friedland has no relevant financial affiliations to disclose. (Updated 03/16/16)

Dr Volberding has served on scientific advisory boards for Bristol-Myers Squibb and Gilead Sciences, Inc. He has also served on data safety monitoring boards for Merck & Co, Inc. (Updated 03/16/16)

Dr del Rio has served as a consultant for InnaVirVax. (Updated 03/16/2016)

Dr Dunne has no relevant financial affiliations to disclose. (Updated 03/16/2016)

Dr Gallant has served as a consultant or advisor to Bristol-Myers Squibb, Gilead Sciences, Inc, Janssen Therapeutics, Merck & Co, Inc, and ViiV Healthcare. He has received research grants or contracts awarded to his institution from AbbVie, Bristol-Myers Squibb, Gilead Sciences, Inc, Janssen Therapeutics, Inc, Merck & Co, Inc, Sangamo BioSciences, and ViiV Healthcare. (Updated 03/16/16)

Dr Sax has received grants and research support awarded to Brigham and Women’s Hospital from Gilead Sciences, Inc, Merck & Co, Inc, and ViiV Healthcare. He has served as a consultant to AbbVie, Bristol-Myers Squibb, Janssen Therapeutics, Gilead Sciences, Inc, ViiV Healthcare, and Merck & Co, Inc. (Updated 03/16/2016)

Dr Gulick has no relevant financial affiliations to disclose. (Updated 03/16/16)

Dr Naggie has received research support paid to her institution from AbbVie, Bristol-Myers Squibb, Gilead Sciences, Inc, Janssen Therapeutics, Tacere Therapeutics, Inc, and Vertex Pharmaceuticals, Inc. She has served as a scientific advisor to AbbVie, Bristol-Myers Squibb, Merck & Co, Inc, and Gilead Sciences, Inc. (Updated 03/16/16) As a volunteer co-chair of the AASLD/IDSA Hepatitis Guidance effort, Dr Naggie has divested herself of any personal financial relationships with commercial entities as of October 1, 2015.

Dr Henrich has no relevant financial affiliations to disclose. (Updated 03/16/2016)

Dr El-Sadr has no relevant financial affiliations to disclose. (Updated 03/16/2016)

IAS–USA CME Staff

Donna M. Jacobsen, Executive Director, has no relevant financial affiliations to disclose (see above).

Cristin M. Toth, CME Project Manager, has no relevant financial affiliations to disclose. (Updated 04/13/15)

 

Contact Information

If you have any questions about this web-based CME activity, please contact the IAS–USA:
425 California Street
Suite 1450
San Francisco, CA   94104-2120
Telephone: 415-544-9400
Fax: 415-544-9401
E-mail: registration@iasusa.org